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The triphenyltin(IV) compound with N-tert-butoxycarbonyl-L-ornithine (Boc-Orn-OH), [Ph3Sn(Boc-Orn-
O)], was synthesized and characterized by elemental analysis, FT-IR, solution 1H, 13C and 119Sn NMR
and ESI mass spectrometry. The organotin(IV) compound inhibited at very low micromolar concentra-
tions the growth of human tumor cell lines HepG2 (hepatocarcinoma cells), MCF-7 (mammary cancer)
and HCT116 (colorectal carcinoma) while it did not affect the viability of non-malignant human-derived
hepatic cells Chang. The mechanism of the antiproliferative effect of Ph3Sn(Boc-Orn-O), investigated on
human hepatoma HepG2 cells, was pro-apoptotic, being associated with externalization of plasma mem-
brane phosphatidylserine, chromatin condensation or fragmentation and mitochondrial dysfunction as
well as with increase of p53 levels.
 2016 Published by Elsevier B.V.1. Introduction
Organotin(IV) derivatives have been prepared and tested in the
past as possible anticancer agents [1–6] and many of them exhib-
ited interesting activity in specific cancer models. Tin-based drugs
represent an excellent alternative to platinum ones as antitumor
agents, having the considerable advantage to display a lower toxi-
city. Triorganotins have demonstrated potential antiproliferative
activity in vitro [7] against human tumor cell lines, which has been
related to their ability to bind to proteins [8,9]. Special attention is
given to organotin(IV) carboxylates with significant cytotoxic
properties against different cancer cell lines [10,11]. Some com-
pounds have shown strong apoptosis inducing character in vitro,
which can be higher than the corresponding activity of cisplatin
or other clinical anticancer drugs [12].
Although the majority of organotin(IV) compounds cause apop-
totic cell death, the exact mechanism of action is not yet clearly
determined [13]. Several researches have been focused onunderstanding the binding mode of organotin(IV) compounds to
biologically relevant ligands [3,14], often using small peptides, as
low-molecular-weight proteins to mimic the metal ion interaction.
The organic ligand facilitates the transport of the compounds
across the cell membrane, while the antitumor activity is due to
dissociated organotin(IV) moieties.
On account of their structural variability, organotin(IV) deriva-
tives of N-substituted amino acids have been extensively studied
[14]. Moreover, also organotin(IV) carboxylates of N-protected
amino acids have shown interesting pharmacological applications
as antitumor agents. Thus, it is of particular interest to examine
the structural variations caused by protecting groups on the amino
nitrogen of the ligand [15]. One of the most widely used N-terminal
protecting groups is the tert-butoxycarbonyl (Boc) group. Boc-
amino acids are often used as substrates, substrate analogues or
competitive inhibitors of proteolytic enzymes. The study of their
conformational preferences is also important for understanding
their interactions with enzymes [16].
Several reports have been published concerning structural char-
acterization and bioactivity as antitumor agents of di- and
tri-organotin(IV) compounds [17]. Following our previous
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tert-butoxycarbonyl-L-arginine [18,19], we extended our work to
the synthesis, structural characterization and biological activity
of a triphenyltin(IV) derivative with N-tert-butoxycarbonyl-L-
ornithine (Boc-Orn-OH) (Fig. 1).
Ph3Sn(Boc-Orn-O) has been synthesized and characterized by
elemental analysis, FT-IR, ESI mass spectrometry, 1H, 13C and
119Sn NMR spectroscopic techniques and its cytotoxic behavior
has been investigated on three human tumor cell lines, HepG2
(hepatocarcinoma cells), MCF-7 (mammary cancer) and HCT116
(colorectal carcinoma) as well as on non-malignant human-
derived hepatic cells (Chang). Moreover, the mechanism of its anti-
tumor activity has been evaluated.2. Experimental
2.1. Materials and physical measurements
Ph3SnOH (Aldrich) and N-tert-butoxycarbonyl-L-ornithine
(Fluka) were used without further purification. Elemental micro-
analyses for C, H and N were performed at the Laboratorio di
Microanalisi, University of Padova, Italy. Infrared spectra were
recorded with a Perkin-Elmer Spectrum One FT-IR spectrometer,
using KBr disc with a resolution of 4 cm1. All NMR spectra were
acquired with an Avance II DMX 400 MHz (9.40 T) spectrometer
(Bruker BioSpin GmbH, Rheinstetten, Germany), operating at
400.15 MHz for protons, 100.63 MHz for 13C, and 149.20 MHz
for 119Sn. One-dimensional 1H and 13C{1H} spectra in CD3OD
and DMSO-d6 solutions were acquired at 27 C with a spectral
width (i.e. SW) of 12 ppm and 200 ppm, respectively. One-dimen-
sional 119Sn{1H} NMR spectra in CD3OD and DMSO-d6 solutions
were recorded at 27 C with a SW of 800 ppm by investigating
four spectral windows with SW = 250 ppm at once in the +200
to 600 ppm range. For 119Sn, Me4Sn was employed as external
reference (119Sn, d = 0.00 ppm). 1H and 13C resonances were cali-
brated on Me4Si as external reference (1H, d = 0.00 ppm; 13C,
d = 0.00 ppm). 119Sn{1H} and 13C{1H} spectra were acquired with
broadband proton power-gated decoupling. For all nuclei, positive
chemical shift had higher frequencies than the reference. LW in
the text is intended as line width at half height. Solutions concen-
trations were ca. 0.5103 M. Solid-state 119Sn{1H} CP-MAS spec-
tra were acquired with NS (i.e. number of transients) equal to
1200, using recycling delays of 2 s, contact time of 6 ms and
acquisiton time of 11.5 ms. Spinning rates of 5 kHz and 7 kHz
were used in order to get the isotropic d119Sn{1H}value. Line
broadening of 75 Hz and zero filling of 16 k points were applied
to the free induction decays (FID) before transformation. After
calibration on the (c-C6H12)4Sn, a power level of 4 dB was applied
in order to get the Hartman–Hahn condition. 119Sn chemical
shifts are given with respect to the solid (c-C6H12)4Sn as sec-
ondary reference [d (119Sn) = 97.0 ppm with respect to Me4Sn].
Solid-state 13C{1H} CP-MAS spectra were acquired with NS = 512
using recycling delays of 3 s, contact time of 2 ms and acquisiton
time of 34 ms. Spinning rates of 5 kHz and 8 kHz were used inFig. 1. N-tert-butoxycarbonyl-L-ornithine (Boc-Orn-OH).order to get the isotropic d(13C) value. Line broadening of 25 Hz
and zero filling of 4 k points were applied to the FID before trans-
formation. A power level of 5.1 dB was applied in order to get the
Hartman–Hahn condition. 13C chemical shifts are given with
respect to the solid admantane as secondary reference [d
(13CH2) = 29.5 ppm; d(13CH) = 38.6 ppm with respect to Me4Si].
Positive-ion and negative-ion electrospray ionization (ESI) mass
spectra were measured on an ion trap analyzer Bruker 3000 +in
the range m/z 60–1500. The compound was dissolved in metha-
nol or acetonitrile, diluted at 0.1–1.0 mg/mL in MeOH/H2O and
acetonitrile/H2O (80/20), and analyzed in ESI-MS by direct infu-
sion at a flow rate of 6 ll/min.2.1.1. Synthesis of Ph3Sn(Boc-Orn-O)
The reaction of Ph3SnOH with Boc-Orn-OH in a 1:1 molar ratio,
led to the formation of the organotin(IV) compound according to
Eq. (1)Ph3SnOHþ Boc-Orn-OH! Ph3SnðBoc-Orn-OÞ þH2O ð1Þ
A solution of Ph3SnOH (0.734 g, 2 mmol) in dry methanol
(15 mL) was added drop wise to a methanol solution (15 mL) of
the ligand (Boc-Orn-OH, 0.464 g, 2 mmol) and left to react, under
stirring, for 4 h. After cooling at room temperature, the solvent
was reduced under vacuum to a small volume (5 mL) using a rotary
evaporator; a white solid residual was obtained, which was filtered
off, washed three times with a total amount of methanol of 50 mL
and dried in vacuo in presence of P4O10. C28H34N2O4Sn:
M = 581.31 g/mol; m.p. = 118 C; Anal.Calc.: C 57.85, H 5.89, N
4.82, Sn 20.42%. Found: C 57.50, H 6.16, N 5.11, Sn 20.31%. IR
(KBr, cm1): 3379 m, 3327w, 3263 m m(NH); 1654 s mas(COO),
1413 m ms(COO), Dm = 241; 280 m mas(sn-C), 227w ms(sn-C). 1H
NMR (400.15 MHz, CD3OD): d (ppm) 7.78–7.76 (br, 6H, o-protons
in SnPh3, |3J(119Sn,1H)| = 59.0 Hz); 7.49–7.42 (br, m, 9H, m- and p-
protons in SnPh3); 3.93 (br,1H, H-2); 2.88 (t, 2H, H-7); 1.81(m,
2H, H-5); 1.66 (m, 2H, H-6); 1.41 (s, 9H, Boc). 13C NMR
(100.63 MHz, CD3OD): d (ppm) 173.4 (C-1); 157.6–158.2 (C-3);
140.8–140.9 (Sn–C6H5 ipso, 1J(119Sn,13C)| = 738 Hz); 137.7 (Sn–
C6H5 ortho, |2J(119Sn,C)| = 43.2 Hz); 129.7 (Sn–C6H5 meta, |3J(119Sn,
C)| = 64.4 Hz); 130.5–130.6 (Sn–C6H5 para, |4J(119Sn,C)| = 13.4 Hz);
80.3 (Cquat-4); 52.5 (C-2); 42.7 (C-7); 29.3 (C-5); 28.8 (C-Boc);
22.3 (C-6). 119Sn NMR (149.20 MHz, CD3OD): d (ppm) 166.8. 1H
NMR (400.15 MHz, DMSO-d6): d (ppm) 7.79–7.78 (d, 6H, o-protons
in SnPh3, |3J(119Sn,C)| = 59.5 Hz); 7.40–7.38 (d, 9H, m- and p-pro-
tons in SnPh3); 3.70 (d, 1H, H-2); 2.39 (t, 2H, H-7); 1.92–1.74 (m,
2H, H-5), 1.51 (d, 2H, H-6), 1.38 (s, 9H, Boc). 13C NMR
(100.63 MHz, DMSO-d6): d (ppm) 170.1 (C-1); 155.3 (C-3);
142.5–141.9 (Sn–C6H5 ipso); 136.1–135.9 (Sn–C6H5 ortho), 2J
(119Sn,C)| = 42.4 Hz; 128.2 (Sn–C6H5 meta, |3J(119Sn,C)| = 59.5 Hz;
128.9 (Sn–C6H5 para); 77.6 (Cquat-4); 50.2 (C-2); 40.9 (C-7); 28.2
(C-Boc); 27.8 (C-5); 21.1 (C-6). 119Sn NMR (149.20 MHz, DMSO-
d6): d (ppm) 125.9, 137.5. CP-MAS 13C NMR (100.63 MHz) for
the ligand: d (ppm) 179.1 (C-1); 156.5 (C-3); 77.6 (Cquat-4); 58.5
(C-2); 40.7 (C-7); 30.9 (C-Boc); 29.2 (C-5); 25.4 (C-6); CP-MAS
13C NMR (100.63 MHz) for the compound: d (ppm) 179.5, 176.1,
171.8 (C-1); 157.4 (C-3); 146.8 (Sn–C6H5 ipso); 143.0 (Sn–C6H5
ortho); 128.6 (Sn–C6H5 meta); 137.8, 134.5 (Sn–C6H5 para); 77.2
(Cquat-4); 58.4, 52.9, 50.4 (C-2); 42.3, 40.7, 38.5 (C-7); 29.6 (C-
Boc); 24.5 (C-5); 22.0 (C-6); CP-MAS 119Sn NMR (149.20 MHz): d
(ppm) -297. ESI-MS: MW = 582. Positive-ion MS: m/z 604.9 [M
+ Na]+; m/z 582.9 [M + H]+; Negative-ion MS: m/z 626.8 [M
+ HCOO]; m/z 580.9 [M-H] traces.
Due to the low solubility of the ligand, 13C{1H} NMR spectra of
Boc-Orn-OH and Ph3Sn(Boc-Orn-O), were recorded also in solid
state to check the compound formation.
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2.2.1. Viability assay in vitro
Ph3Sn(Boc-Orn-O) was dissolved in dimethyl sulfoxide (DMSO)
and then diluted in culture medium so that the effective DMSO
concentration did not exceed 0.1%. HepG2, MCF-7 and HCT116
tumor cell lines and human hepatic Chang liver cells were pur-
chased from American Type Culture Collection, Rockville, MD,
USA. All of them were grown in RPMI medium supplemented with
L-glutamine (2 mM), 10% fetal bovine serum (FBS), penicillin
(100 U/mL), streptomycin (100 lg/mL) and gentamicin (5 lg/mL).
HepG2 culture medium also contained sodium pyruvate
(1.0 mM). Cells were maintained in log phase by seeding twice a
week at a density of 3  108 cells/L in humidified 5% CO2 atmo-
sphere, at 37 C. In all experiments, cells were made quiescent
through overnight incubation before the treatment with the com-
pounds or vehicle alone (control cells). No differences were found
between cells treated with DMSO 0.1% and untreated cells in terms
of cell number and viability.
Cytotoxic activity of Ph3Sn(Boc-Orn-O) against three human
tumor cell lines HepG2, MCF-7, HCT116 and human hepatic Chang
liver cells was determined by the MTT colorimetric assay based on
the reduction of 3-(4,5-dimethyl-2-thiazolyl)bromide-2,5-diphe-
nyl-2H-tetrazolium (MTT) [20] to purple formazan by mitochon-
drial dehydrogenases of living cells. This method is commonly
used to illustrate inhibition of cellular proliferation. Monolayer
cultures were treated for 24 h with various concentrations (0.1–
5 lM) of the drug. Cisplatin was used for comparison.
Briefly, all cell lines cells were seeded at 2  104 cells/well in 96-
well plates containing 200 lL RPMI. After an overnight incubation,
cells were washed with freshmedium and incubated with the com-
pounds in RPMI. After 24 h incubation, cells were washed, and
50 lL FBS-free medium containing 5 mg/mL MTT were added. The
medium was discarded after 2 h incubation at 37 C by centrifuga-
tion, and formazan blue formed in the cells was dissolved in DMSO.
The absorbance, measured at 570 nm in a microplate reader (Bio-
RAD, Hercules, CA), of MTT concentration at which 50% of cells
remained viable relative to the control. Each experiment was
repeated at least three times in triplicate to obtain the mean values.2.2.2. Measurement of phosphatidylserine exposure
HepG2 cells were seeded in triplicate in 24-wells culture plates
at a density of 5.0  104 cells/cm2. After overnight incubation, the
cells were washed with fresh medium and incubated with the 1–
2 lM compound in RPMI. After 24 h, cells were harvested by
trypsinization, collected by centrifugation and submitted to
Annexin V-FITC/PI double staining (eBioscience, San Diego, CA) as
reported [19]. Samples of at least 1.0  104 cells were analyzed
by fluorescence-activated cell sorting (FACS) analysis by Epics XLTM
flow cytometer using Expo32 software (Beckman Coulter, Fuller-
ton, CA), using appropriate 2-bidimensional gating method.2.2.3. Acridine orange and ethidium bromide morphological
fluorescence dye staining
Dual staining with acridine orange (AO)/ethidium bromide (EB)
allows enumeration of populations of viable non apoptotic, viable
(early) apoptotic, nonviable (late) apoptotic, and necrotic cells
[21]. Briefly, after HepG2 cells were treated with Ph3Sn(Boc-Orn-
O) at 1–2 lM concentration for 24 h, the medium was discarded.
Cells were washed with saline 5 mM phosphate buffer (PBS) and
then incubated with 100 lL PBS containing 100 lg/mL of EB plus
100 lg/mL of AO. After 20 s, EB/AO solution was discarded and
cells immediately visualized by means of fluorescent microscope
equipped with an automatic photomicrograph system (Leica,
Wetzlar, Germany). Multiple photos were taken at randomlyselected areas of the well to ensure that the data obtained are
representative.
2.2.4. Measurement of mitochondrial transmembrane potential
Mitochondrial transmembrane potential (Dwm) was assayed by
flow cytofluorometry, using the cationic lipophilic dye 3,30-dihexy-
loxacarbocyanine iodide [DiOC6(3)] (Molecular Probes,Inc.) which
accumulates in themitochondrialmatrix. Changes inmitochondrial
membrane potential are indicated by a reduction in the DiOC6-
induced fluorescence intensity. Cells were incubated with DiOC6(3)
at a40 nmol/Lfinal concentration, for 15 minat 37 C.After centrifu-
gation, cells were washed with PBS and suspended in 500 lL PBS.
Samples of at least 1  104 cells for each sample were subjected to
FACS analysis by Epics XLTM flow cytometer as above reported.
2.2.5. Measurement of cytosolic calcium
Intracellular Ca2+ concentration in a single cell was measured
using fluo-3/AM as a fluorescent Ca2+ probe, whose intensity is
directly representative of cellular concentration of the ion. Fluo-
3/AM, at 2 mM final concentration, was added into the cell med-
ium 40 min before the end of the treatment. After centrifugation,
cells were washed with PBS and suspended in 500 lL PBS. The flu-
orescent intensities were analyzed by fluorescence-activated cell
sorting analysis in at least 1x104 cells for each sample.
2.2.6. Measurement of intracellular reactive oxygen species (ROS)
ROS level was monitored by measuring fluorescence changes
that resulted from intracellular oxidation of dichloro-dihydro-fluo-
rescein-diacetate (DCFH-DA). DCFH-DA, at 10 mM final concentra-
tion, was added to the cell medium 30 min before the end of the
treatment. The cells were collected by centrifugation for 5 min at
2000 rpm at 4 C, washed, suspended in PBS and immediately sub-
jected to fluorescence-activated cell sorting analysis. At least
1  104 cells were analyzed for each sample.
2.2.7. Western blot analysis
After treatment with the compound, protein extracts were pre-
pared and equal amounts of protein samples (80 lg/lane), sub-
jected to SDS-PAGE and transferred to nitrocellulose membrane
as previously reported [21]. The immunoblot was incubated over-
night at 4 C with blocking solution (5% skim milk), followed by
incubation with anti-PARP monoclonal antibody (clone D-1, Cat
No. SC-365315, Santa Cruz Biotechnology, Santa Cruz, CA), or
anti-p53 (FL-393, Cat No SC-6243, Santa Cruz Biotechnology) for
1 h at room temperature. Blots were washed two times with
Tween 20/Tris-buffered saline (TTBS) and incubated with a
1:2000 dilution of horseradish peroxidase (HRP)-conjugated anti-
IgG antibody (Dako Denmark, Glostrup, Denmark) for 1 h at room
temperature. Blots were again washed five times with TTBS and
then developed by enhanced chemiluminescence (Amersham Life
Science, Arlington Heights, IL, U.S.A.). Immunoreactions were also
performed using b-actin antibody as loading controls.
2.2.8. Statistical analysis
Results are given as mean ± SD. Three independent observations
were carried out for each experiment replicated three times. Com-
parison between matched-paired samples was by Student’s t test.
In all cases, significance was accepted if the null hypothesis was
rejected at the P < 0.05 level.
3. Results and discussion
3.1. Spectroscopic data
The IR bands of compound were assigned by comparison with
the IR spectra of the free amino acid (N-tert-butoxycarbonyl-L-
Scheme 1. Speculative origin of the fragment C10H18N2O3.
Fig. 2. Effect of Ph3Sn(Boc-Orn-O) on survival of different human tumor cell lines.
Cells were treated with the test compound and cell survival was measured after
24 h by MTT assay in comparison to cells treated with vehicle alone (control).
Table 1
IC50 values (lM) for the in vitro anti-proliferative activity of triphenyltin(IV)
compound and cisplatin, determined by MTT test, on different human tumor cell
lines.
Compound MCF-7 IC50 ± SD
HepG2 HTC116
Ph3Sn(Boc-Orn-O) 0.52 ± 0.04 1.08 ± 0.09 2.24 ± 0.18
Cisplatin 11.2 ± 1.5 64.3 ± 4.3 46.5 ± 3.5
Values are the mean ± SD of three separate experiments in triplicate.
Fig. 3. Cytotoxicity of Ph3Sn(Boc-Orn-O) on HepG2 tumor liver cells in comparison
with non-malignant human-derived hepatic cells Chang. Cells were treated with
the test compound and cell survival was measured after 24 h by MTT assay in
comparison to cells treated with vehicle alone (control). With respect to control,
values were significant with ⁄P < 0.05 or ⁄⁄P < 0.0001 (Student’s t-test).
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SnOH). The vibration at 3379 cm1 in the IR spectra of the ligand
attributed to the m(N–H), remains unaltered in the compound. Ph3-
SnOH exhibits a m(OH) absorption band of medium intensity at
3617 cm1, which is not observed in the Ph3Sn(Boc-Orn-O) due
to the loss of the OH group on binding to the ligand. The infrared
spectrum of the free ligand shows a band at ca. 1631 cm1 corre-
sponding to the vibrational stretching mode masym(COO) of the
carboxylate moiety. After deprotonation and binding to tin atom,
this band is replaced by a strong absorption at 1654 cm1, while
the corresponding ms(COO) at 1413 cm1 remains unshifted. The
considerable shift of the masym(COO) vibration upon coordination
in Ph3Sn(Boc-Orn-O) is due to the binding to the metal through
the carboxyl oxygen atom. The criterion of the separation between
the symmetric and asymmetric stretching wavenumbers of the
carboxylate moiety, Dm = [m(COO)asym–m(COO)sym], has been
applied to ascertain its bidentate/chelation or monodentate coordi-
nation type [24]. Although a clear line between the two categories
cannot be drawn, the observed value of Dm (241 cm1) strongly
points to a monodentate coordination of the carboxylate group of
the ligand to the tin atom [25]. For a bridging or chelating carboxy-
late group, Dm would be expected to be <150 cm1, as widely
observed in the infrared spectra of triorganotin(IV) carboxylates
[26]. A medium intensity band corresponding to the sn-O stretch-
ing mode of vibration appears at 447 cm1, while the bands at 280
and 227 cm1 are attributed to mas(sn-C) and ms(sn-C) stretching
modes, respectively. Thus, the presence of both asymmetric and
symmetric stretching vibrations in the infrared spectra of the com-
pound in the solid state rules out planar arrangement of the three
sn-Ph bonds. The appearance of two new bands of strong intensity
in the IR spectra of Ph3Sn(Boc-Orn-O) at 693 and 722 cm1 may be
assigned to the C-H out-of-plane deformation vibrations [27]. The
compound also shows the characteristic Whiffen Y-mode absorp-
tion at 450 cm1, typical of the covalent phenyl-tin bonds [28].
The measured 1H, 13C and 119Sn chemical shifts, in ppm, in CD3-
OD and DMSO-d6 solutions, are given in the experimental section.
13C NMR resonances for the free ligand in solution could not be
recorded due to its limited solubility. The resonances for the organ-
otin(IV) compound are compared with the free ligand L-ornithine
[29]. In the 1H NMR spectra of Ph3Sn(Boc-Orn-O), proton reso-
nances experience a shift towards higher frequencies for H-5, H-
6 and H-7, while H-2 and Boc’s protons remain almost unchanged.
The resonances ascribed to the aromatic protons of the phenyl
groups, appeared as two well separated sets of multiplets in the
regions centered around 7.78 and 7.42 ppm in CD3OD, and 7.79
and 7.38 in DMSO-d6. In addition to these signals, 1H NMR spectra
of Ph3Sn(Boc-Orn-O) showed one signal at 1.41 ppm in CD3OD and
1.38 ppm in DMSO-d6, corresponding to the protons of the Boc
group. The signal of the carboxylic carbon (C-1) is observed at
173.4 ppm in CD3OD and 170.1 ppm in DMSO-d6 solutions. Ph3Sn
(Boc-Orn-O) exhibits the signals of the ipso-carbon atoms of the
phenyl ring at 140.8 and 140.9 ppm in CD3OD, while in DMSO-d6
these signals are found at 142.05 and 141.98 ppm: the presence
of these two peaks also indicate two different symmetries around
the central Sn atom. In CD3OD, the 1J(119Sn,13C) value of 738 Hz, is
closer to the low limit of the typical 1J(119Sn,13C) range (750–
850 Hz) [30–32] for penta-coordinated triphenyltin(IV) com-
pounds rather than to the range (550–650 Hz) of tetra-coordinated
ones. In CD3OD solution, the measured 119Sn chemical shift of -
166.8 ppm (LW = 380 Hz) for organotin(IV) compound, lies at the
boundary between tetra- and penta-coordinated tin [30,18], even
if it is more shifted towards a penta-coordinated tin arrangement.
In addition, the large measured LW for the tin signal indicates the
occurrence of a dynamic process conceivably due to solvent-tin
exchange. In order to check the effect of the solvent upon the d
(119Sn), a further 119Sn NMR spectrum has been acquired inDMSO-d6 solution. Two signals, with LW values smaller than in
methanol solution, were found at -125.3 (LW ﬃ 120 Hz) and
137.0 ppm (LW ﬃ 120 Hz), again pointing to penta-coordination
on the tin center. The two similar d(119Sn) values indicate a slight
symmetry variation around the tin center. Moreover, despite the
greater coordinating ability of DMSO-d6 relative to CD3OD, in
DMSO-d6 the observed signals were more deshielded than in
CD3OD solution, most likely due to the occurrence of weaker
sn—DMSO interaction. These findings highlight the existence of
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the metal center is also involved in tin-solvent exchange.
In order to distinguish between the spectroscopic data relating to
a monomeric or to a long-chain polymeric structure, the mass spec-
tral data for the organotin(IV) compound were recorded.
Tin-containing ions are known to form dimeric and polymeric spe-
cies [33] and indeed dimeric ions and adducts with sodium and
hydrogenwere found. All the ions containing tinwereobservedwith
the expected isotopic distribution and the given attributions were
done after comparison with the simulated spectra obtained by the
native software of our instrument. In the positive mode, all the ions
can be relatedwith themass of our compoundMorwith the dimeric
cluster 2 M and fragmentations from these species. All the
principal ions found can be attributed as follows: m/z 1185.0 and
1163.0 [2 M + Na]+ and [2 M + H]+ respectively; m/z 953.0 andFig. 4. Ph3Sn(Boc-Orn-O) induces dose-dependent apoptosis in HepG2 cells. (A) Percenta
flow cytometry. (B) Fluorescence micrographs of ethidium bromide/acridine orange do
cleavage by immunoblotting with densitometric analysis of the immunoblots. Data of th
with vehicle. Representative images of three experiments with comparable results.931.0 [M-H + Ph3Sn + Na]+ and [M + Ph3Sn]+ respectively; m/z
819.0 [M + C10H18N2O3 + Na]+; m/z 716.8 [(Ph3Sn)2O + H]+ found
also by others [34]; m/z 604.9 and 582.9 [M + Na]+ and [M + H]+
respectively; m/z 450.9 [2C10H18N2O3 + Na]+; m/z 236.9
[C10H18N2O3 + Na]+, where the C10 residue could be originated from
the fragmention of Ph3Sn(Boc-Orn-O) according to Scheme 1. It is
worthy to note that no peaks derived from the free Boc-Orn-OH
were detected, and that the C10 residue found in the analysis of
Ph3Sn(Boc-Orn-O) was not observed during the analysis of the free
Boc-Orn-OH in similar conditions. Our organotin(IV) compound
was also investigated applying a negative voltage, again revealing
ions originated from the presumed structure as deprotonated species
or as adducts with formiate such as:m/z 812.9 [M + BocOrn-O],m/z
760.7 [(Ph3Sn)2O + HCOO]; m/z 626.8 [M + HCOO]-, m/z 580.9
[M-H] only present in traces, andm/z 231.1 [Boc-Orn-O].ge of Annexin V/propidium iodide (PI) double-stained HepG2 cells, as determined by
uble-stained HepG2 cells in 200 magnification. (C) Poly(ADP-ribose) polymerase
e densitometric analysis are means and standard deviations. Control, cells treated
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3.2.1. Cytotoxic activity
The in vitro cytotoxicity of Ph3Sn(Boc-Orn-O) against human
tumor cell lines HepG2, HTC116 and MCF-7 was evaluated using
MTT metabolic assay. After 24 h of incubation, a dose dependent
antiproliferative effect at very low micromolar concentrations of
the compound toward all the studied cancer cell lines was mea-
sured (Fig. 2). Table 1 reports the concentration of Ph3Sn(Boc-
Orn-O) required to inhibit 50% of cell proliferation when compared
to untreated cells (IC50).
In addition, cytotoxicity of cisplatin, one of the most widely
used antitumor drugs in clinical practice, has been included. OnFig. 5. Effects of Ph3Sn(Boc-Orn-O) on the activation of mitochondrial dysfunction
dihexyloxacarbocyanine iodide-treated cells, as determined by flow cytometry. (B) Ca2+
analysis. (C) p53 level by immunoblotting with densitometric analysis of the immunobl
cells treated with vehicle. Representative images of three experiments with comparabledirect comparison with cisplatin, the antiproliferative activity of
synthesized organotin(IV) derivative is from 20 to 60 times stron-
ger, being the highest triphenyltin(IV) compound/cisplatin activity
ratio observed, under the investigated conditions, in the HepG2
cells.
In order to determine the selectivity in the in vitro cytotox-
icity of organotin(IV) compound, some additional experiments
were conducted on non-malignant human-derived hepatic cells
Chang. As shown in Fig. 3, at the concentrations effective to
totally inhibit the growth of HepG2 liver tumor cells, Ph3Sn
(Boc-Orn-O) shows only a modest effect on the viability of
normal-like Chang cells, indicating selectivity towards cancer
cells.in HepG2 cells. (A) The Dwm was detected by fluorescence intensity of 3,30-
levels were assayed after cell loading with fluo-3/AM followed by flow cytometry
ots. Data of the densitometric analysis are means and standard deviations. Control,
results.
Fig. 6. Ph3Sn(Boc-Orn-O) caused dose-dependent ROS production in HepG2 cells. ROS were detected by fluorescence intensity of 20 ,70-dichlorofluorescin diacetate-treated
cells, as determined by flow cytometry. Control, cells treated with vehicle. Representative images of three experiments with comparable results.
M.A. Girasolo et al. / Inorganica Chimica Acta 456 (2017) 1–8 73.2.2. Induction of apoptosis in HepG2 cells
To determine whether the antiproliferative effect of Ph3Sn(Boc-
Orn-O) was due to apoptosis, HepG2 cells were treated with the
compound for 24 h, stained with both propidium iodide (PI) and
Annexin V-fluorescein isothiocyanate (FITC), and analyzed by flow
cytometry. The chosen concentrations were selected on the basis
that they represented IC50 and twice the IC50 value. As shown in
Fig. 4A, the control cells stained negative for both Annexin V-FITC
and PI. On the other hand, HepG2 cells treated with increasing
doses, showed increased proportions of Annexin V-positive cells,
indicating that they were at an early stage of apoptosis. The double
positive staining of particular cells also increased, which revealed
that these cells were at a late apoptotic stage. To confirm apoptotic
mechanism of cytotoxicity of Ph3Sn(Boc-Orn-O), we carried out
morphological evaluation of HepG2 cells using AO and EB double
staining. After 24 h of treatment with 1 lM of Ph3Sn(Boc-Orn-O),
fluorescent microscopy revealed the appearance of cells containing
bright green patches in the nuclei as a consequence of chromatin
condensation and nuclear fragmentation, which are typical fea-
tures of apoptosis. Moreover, after treatment with the compound
at 2 lM concentration, fluorescing orange cells owing to increase
of cell permeability to ethidium bromide, cell shrinkage and
nuclear fragmentation were also evident as observed for cells in
late apoptosis (Fig. 4B).
One of the key executioners of the apoptotic cell death is cas-
pase 3, responsible for proteolytic cleavage of many key proteins,
including poly(ADP-ribose) polymerase-1 (PARP-1). In comparison
with control cells, high levels of the 89 kD cleaved product from
PARP-1, with a decrease of the 116 kD native protein, were
observed in HepG2 cells after 24 treatment with Ph3Sn(Boc-Orn-
O) (Fig. 4C). Taken together, these findings provided strong evi-
dence that the synthesized Ph3Sn(Boc-Orn-O) induced apoptosis
in HepG2 cells.
3.2.3. Mitochondrial damage
In many systems, apoptosis is associated with the loss of mito-
chondrial inner membrane potential (Dwm) which is responsible
for the release of some pro-apoptotic factors from the organelle.
We investigated the involvement of mitochondria in apoptosis
induced by the tin compound using DiOC6(3), a fluorescent mito-
chondria-specific and voltage-dependent dye. The results, reported
in Fig. 5A, indicate that treatment of HepG2 cells with 1 lM of Ph3-
Sn(Boc-Orn-O) for 24 h, induced a marked dissipation of Dwm as
indicated by decreased mitochondrial DiOC6-red.
Owing to mitochondrial dysfunction, perturbation of the intra-
cellular calcium level is expected. A Fluo-3/AM staining followed
by flow cytometry analysis, gave evidences that, in comparisonwith control cells, treatment of HepG2 cells with Ph3Sn(Boc-Orn-
O) also caused a net elevation of cellular Ca2+ content, evident by
the increment of fluorescence of the ion probe (Fig. 5B).
To understand more about the apoptosis induction mechanism
caused by Ph3Sn(Boc-Orn-O), the levels of p53 protein was
assessed by Western blot. p53 is a key suppressor of tumor regula-
tors in the apoptotic process and possesses pro-apoptotic activity
through modulation of the BCL-2 family proteins that control the
mitochondrial membrane permeability. As shown in Fig. 5C, 24 h
treatment of HepG2 cells with 1 lM of organotin(IV) compound,
caused threefold increase of p53 levels. These findings provide evi-
dence that the cytotoxicity of the compound is related to the
induction of a p53-dependent activation of the mitochondrial
pathway of apoptosis.3.2.4. ROS generation
Since the generation of intracellular ROS may be related to
mitochondrial dysfunction and induction of apoptosis in various
cell types, we explored whether our organotin(IV) compound could
stimulate ROS generation in HepG2 cells. As illustrated in Fig. 6, the
generation of ROS, cytofluorimetrically detected by the fluorescent
dye DCFH-DA, dramatically increased in tin compound-treated
cells compared with that of the control group, with a clear dose-
response mechanism.4. Conclusions
Ph3Sn(Boc-Orn-O) showed strong cytotoxic and anticancer
effects. Compared to cisplatin, organotin(IV) compound exhibited
much higher antiproliferative activity in vitro with IC50 values for
cell growth proliferation 20–60 times larger than those of cis-platin
toward all the investigated cancer cell lines (HepG2, HTC116 and
MCF-7).
Both oxidative damage and increased concentration of intracel-
lular calcium ions seem to be the main events contributing to tri-
organotin-induced apoptosis in different panels of human cancer
cell lines [35] and promotion of oxidative and DNA damage in rats
tributyltin has been detected [36]. There are multiple DNA damage
detection and repair systems in a cell but every type of DNA dam-
age is reported to the p53 protein and its pathway [37–39], so that
p53-triggered apoptosis plays an important role in regulating cell
survival. Similarly, our findings show that apoptosis triggered by
our organotin(IV) compound in human hepatocarcinoma cells
involves a p53-dependent activation of the mitochondrial pathway
of apoptosis, ROS formation and Ca2+ influx in the cytosol.
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